腫瘍浸潤リンパ球の世界市場レポート 2024年

腫瘍浸潤リンパ球の市場規模は近年急速に拡大しています。2023年の93億4,000万米ドルから2024年には107億2,000万米ドルへと、CAGR14.8％で拡大します。過去の期間に見られた成長は、がん罹患率の上昇、研究イニシアティブへの資金提供の増加、がん治療に対する規制当局の承認、がんに関連する問題に対する意識の高まり、さまざまな治療法の有効性を示す注目すべき臨床的成功など、いくつかの要因に起因しています。

個別化治療に対する患者からの需要の高まりは、腫瘍浸潤リンパ球市場の成長を当面促進するものと思われます。個別化療法は、遺伝的体質、分子形質、ライフスタイル、環境的影響など、個人の明確な特徴に合わせて医療行為を調整するものです。個別化治療に腫瘍浸潤リンパ球を取り入れることで、各患者のユニークな免疫プロファイルを活用し、がん治療戦略を強化することを目的としています。2023年2月、個別化医療連合（Personalized Medicine Coalition）は、2022年に米国食品医薬品局が承認した新薬のうち、個別化治療薬が34％を占め、それ以前の8年間はいずれも25％以上の承認に寄与していたと報告しました。個別化治療に対する患者の需要の増加は、腫瘍浸潤リンパ球市場の成長を推進する主要な要因として浮上しています。

北米は、2023年の腫瘍浸潤リンパ球市場において最大の地域でした。腫瘍浸潤リンパ球市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 腫瘍浸潤リンパ球市場の特徴

第3章 腫瘍浸潤リンパ球市場の動向と戦略

第4章 腫瘍浸潤リンパ球市場- マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の腫瘍浸潤リンパ球市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 腫瘍浸潤リンパ球市場セグメンテーション

• 世界の腫瘍浸潤リンパ球市場、解剖学的セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• CD3
• CD8
• CD16
• CD56
• CD4
• CD57
• CD169
• CD68
• FOXP3
• 世界の腫瘍浸潤リンパ球市場、コンポーネント別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• T細胞
• B細胞
• ナチュラルキラー細胞
• 世界の腫瘍浸潤リンパ球市場、用途別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 黒色腫
• 子宮頸がん
• 卵巣がん
• その他の用途
• 世界の腫瘍浸潤リンパ球市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• がん研究センター
• クリニック

第7章 腫瘍浸潤リンパ球市場の地域および国分析

• 世界の腫瘍浸潤リンパ球市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の腫瘍浸潤リンパ球市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋の腫瘍浸潤リンパ球市場

第9章 中国の腫瘍浸潤リンパ球市場

第10章 インドの腫瘍浸潤リンパ球市場

第11章 日本の腫瘍浸潤リンパ球市場

第12章 オーストラリアの腫瘍浸潤リンパ球市場

第13章 インドネシアの腫瘍浸潤リンパ球市場

第14章 韓国の腫瘍浸潤リンパ球市場

第15章 西欧の腫瘍浸潤リンパ球市場

第16章 英国の腫瘍浸潤リンパ球市場

第17章 ドイツの腫瘍浸潤リンパ球市場

第18章 フランスの腫瘍浸潤リンパ球市場

第19章 イタリアの腫瘍浸潤リンパ球市場

第20章 スペインの腫瘍浸潤リンパ球市場

第21章 東欧の腫瘍浸潤リンパ球市場

第22章 ロシアの腫瘍浸潤リンパ球市場

第23章 北米の腫瘍浸潤リンパ球市場

第24章 米国の腫瘍浸潤リンパ球市場

第25章 カナダの腫瘍浸潤リンパ球市場

第26章 南米腫瘍浸潤リンパ球市場

第27章 ブラジル腫瘍浸潤リンパ球市場

第28章 中東の腫瘍浸潤リンパ球市場

第29章 アフリカ腫瘍浸潤リンパ球市場

第30章 腫瘍浸潤リンパ球市場の競合情勢と企業プロファイル

• 腫瘍浸潤リンパ球市場の競合情勢
• 腫瘍浸潤リンパ球市場の企業プロファイル
  • Bellicum Pharmaceuticals Inc.
  • Novartis AG
  • Pfizer Inc.
  • Precision BioScience Inc.
  • Bluebird Bio Inc.

第31章 世界の腫瘍浸潤リンパ球市場の競合ベンチマーキング

第32章 世界の腫瘍浸潤リンパ球市場競争力ダッシュボード

第33章 腫瘍浸潤リンパ球市場における主要な合併と買収

第34章 腫瘍浸潤リンパ球市場の将来展望と可能性分析

第35章 付録

“Tumor Infiltrating Lymphocytes Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tumor infiltrating lymphocytes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tumor infiltrating lymphocytes? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The tumor infiltrating lymphocytes market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Anatomy: CD3; CD8; CD16; CD56; CD4; CD57; CD169; CD68; FOXP3
• 2) By Component: T-Cells; B-Cells; Natural Killer Cells
• 3) By Application: Melanoma; Cervical Cancer; Ovarian Cancer; Other Applications
• 4) By End-User: Hospitals; Cancer Research Centers; Clinics
• Companies Mentioned: Bellicum Pharmaceuticals Inc.; Novartis AG; Pfizer Inc.; Precision BioScience Inc.; Bluebird Bio Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Tumor infiltrating lymphocytes (TILs) are immune cells capable of identifying and eliminating cancer cells upon entering a tumor through the bloodstream. They are extracted from a patient's tumor, expanded in large quantities within a laboratory setting, and subsequently reintroduced into the patient's body to assist the immune system in targeting and destroying cancer cells.

Key components or anatomies of tumor-infiltrating lymphocytes encompass CD3, CD8, CD16, CD56, CD4, CD57, CD169, CD68, and FOXP3. CD3, also known as the cluster of differentiation 3, constitutes a complex protein structure involving T-cells, B-cells, and natural killer cells. These components find applications in various cancers such as melanoma, cervical cancer, ovarian cancer, among others. The end-users of these lymphocytes include hospitals, cancer research centers, and clinics involved in cancer treatment and research.

The tumor infiltrating lymphocytes market research report is one of a series of new reports from. The Business Research Company that provides tumor infiltrating lymphocytes market statistics, including tumor infiltrating lymphocytes industry global market size, regional shares, competitors with a tumor infiltrating lymphocytes market share, detailed tumor infiltrating lymphocytes market segments, market trends and opportunities, and any further data you may need to thrive in the tumor infiltrating lymphocytes industry. This tumor infiltrating lymphocytes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tumor infiltrating lymphocytes market size has grown rapidly in recent years. It will grow from $9.34 billion in 2023 to $10.72 billion in 2024 at a compound annual growth rate (CAGR) of 14.8%. The growth observed in the historical period can be attributed to several factors, including the rise in cancer incidence rates, increased funding for research initiatives, regulatory approvals for cancer treatments, heightened awareness about cancer-related issues, and notable clinical successes showcasing the efficacy of various treatments.

The tumor infiltrating lymphocytes market size is expected to see rapid growth in the next few years. It will grow to $18.32 billion in 2028 at a compound annual growth rate (CAGR) of 14.3%. The projected growth in the forecast period is driven by several factors, including advancements in pipeline developments, a rise in healthcare expenditure, the emergence of new markets, strategic collaborations and alliances, continued regulatory support, and growing demand from patients for innovative treatments. Key trends expected in the forecast period encompass significant advancements in immunotherapy, increased focus on research and development initiatives, evolving regulatory landscapes impacting the healthcare sector, the expanding scope of personalized medicine, and heightened market competition within the industry.

The increasing prevalence of cancer patients is anticipated to drive the growth of the tumor-infiltrated lymphocytes (TIL) market. Cancer, characterized by uncontrolled cell growth and spread in the body, poses significant health challenges, some of which can be life-threatening. Tumor-infiltrating lymphocytes, a specific type of immune cell, play a crucial role in identifying and eliminating cancer cells. These lymphocytes are harvested from a patient's tumor, extensively cultured in a laboratory, and subsequently reintroduced into the patient to support the immune system in targeting and destroying cancer cells. Notably, as of January 2022, the American Cancer Society reported projections of 1,918,030 new cancer cases and 609,360 cancer-related deaths for the year, highlighting an increase compared to 2020 figures of 1,806,590 new cancer cases and 606,520 projected deaths. This rise in cancer cases underscores the driving force behind the expansion of the tumor-infiltrated lymphocyte market.

The growing demand from patients for personalized therapies is poised to fuel the growth of the tumor-infiltrating lymphocyte market in the foreseeable future. Personalized therapies involve tailoring medical treatments to an individual's distinct characteristics, including genetic makeup, molecular traits, lifestyle, and environmental influences. The incorporation of tumor-infiltrating lymphocytes in customized treatments aims to enhance cancer treatment strategies by leveraging the unique immune profiles of each patient. In February 2023, the Personalized Medicine Coalition reported that personalized medications constituted 34% of new drug approvals by the US Food and Drug Administration in 2022, contributing to at least 25% of approvals in each of the preceding eight years. The increasing patient demand for personalized therapies emerges as a key driver propelling the growth of the tumor-infiltrating lymphocyte market.

Technological advancements emerge as a prominent trend gaining traction in the tumor-infiltrating lymphocytes market, with major companies strategically focusing on developing cutting-edge solutions to enhance their market positions. An illustrative example is Obsidian Therapeutics Inc., a US-based biotechnology firm specializing in engineered tumor-infiltrating lymphocytes (TIL cells) and gene treatments. In May 2022, Obsidian Therapeutics announced the introduction of cytoDRIVE technology, showcasing its ability to precisely regulate the time and level of protein activity using FDA-approved small chemicals. This technological innovation holds significant potential for treating solid cancers by employing potent cytokines such as IL12 to support cell treatments. The study revealed that various cytokines, including IL12, IL23, IL2, and IFN, could be robustly and reversibly regulated, potentially enabling their safe utilization in adoptive cell therapy applications.

Major players in the tumor-infiltrating lymphocytes market are adopting a strategic partnership approach to foster the development of innovative treatments centered around gene editing. Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits. In April 2021, Vertex Pharmaceuticals Incorporated, a US-based biopharmaceutical company, entered into a partnership licensing agreement with Obsidian Therapeutics Inc. The collaboration is dedicated to advancing groundbreaking medicines that control gene editing for the treatment of critical disorders. Vertex's well-established scientific and clinical capabilities in small molecule, cell, and genetic therapies are complemented by Obsidian's cytoDRiVE platform technology. This technology allows the development of gene-editing drugs with easily controlled therapeutic activity using small molecules. The collaboration aims to expedite the delivery of these innovative approaches to patients. By building on and expanding Vertex's expertise in small molecules and genetic medicines, the partnership with Obsidian positions Vertex at the forefront of advancements in controlled cell and gene treatments.

In January 2021, Turnstone Biologics Corporation, a leading US-based diagnostic biotechnology firm specializing in cancer immunotherapies, successfully acquired Myst Therapeutics Inc. The acquisition, conducted for an undisclosed amount, grants Turnstone Biologics Corp. exclusive access to Myst Therapeutics Inc.'s cutting-edge technology, comprehensive research and development resources, existing development partnerships, and a robust portfolio of tumor-infiltrating lymphocytes (TIL) projects. Myst Therapeutics Inc., a prominent US-based biotechnology company, is dedicated to advancing cancer immunotherapies through the utilization of tumor-infiltrating lymphocytes (TIL) and the development of innovative T-cell therapeutics designed for the treatment of solid tumors.

Major companies operating in the tumor infiltrating lymphocytes market report are Bellicum Pharmaceuticals Inc., Novartis AG, Pfizer Inc., Precision BioScience Inc., Bluebird Bio Inc., TCR2 Therapeutics Inc., Fate Therapeutics Inc., Merck KGaA, Autolus Therapeutics PLC., Eli Lilly and Company, Oxford Biomedica PLC., Seeking Alpha Ltd., Unum Therapeutics Inc., Amgen Inc., Gilead Sciences Inc., Sorrento Therapeutics Inc., TILT Biotherapeutics Ltd., Iovance Biotherapeutics Inc., Adaptimmune Therapeutics plc, Precision BioSciences, Atara Biotherapeutics Inc., BioNTech SE, CARsgen Therapeutics Ltd., Cellectis S.A., Celyad Oncology SA, CRISPR Therapeutics AG, Editas Medicine Inc., Intellia Therapeutics Inc., Kiadis Pharma N.V., MaxCyte Inc. .

North America was the largest region in the tumor infiltrating lymphocytes market in 2023. The regions covered in the tumor infiltrating lymphocytes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the tumor infiltrating lymphocytes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tumor infiltrating lymphocytes market consists of sales of autologous TILs (tumor infiltrating lymphocytes), allogeneic TILs, and engineered TILs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Tumor Infiltrating Lymphocytes Market Characteristics

3. Tumor Infiltrating Lymphocytes Market Trends And Strategies

4. Tumor Infiltrating Lymphocytes Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Tumor Infiltrating Lymphocytes Market Size and Growth

• 5.1. Global Tumor Infiltrating Lymphocytes Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Tumor Infiltrating Lymphocytes Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Tumor Infiltrating Lymphocytes Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Tumor Infiltrating Lymphocytes Market Segmentation

• 6.1. Global Tumor Infiltrating Lymphocytes Market, Segmentation By Anatomy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• CD3
• CD8
• CD16
• CD56
• CD4
• CD57
• CD169
• CD68
• FOXP3
• 6.2. Global Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• T-Cells
• B-Cells
• Natural Killer Cells
• 6.3. Global Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Melanoma
• Cervical Cancer
• Ovarian Cancer
• Other Applications
• 6.4. Global Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Cancer Research Centers
• Clinics

7. Tumor Infiltrating Lymphocytes Market Regional And Country Analysis

• 7.1. Global Tumor Infiltrating Lymphocytes Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Tumor Infiltrating Lymphocytes Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Tumor Infiltrating Lymphocytes Market

• 8.1. Asia-Pacific Tumor Infiltrating Lymphocytes Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Tumor Infiltrating Lymphocytes Market

• 9.1. China Tumor Infiltrating Lymphocytes Market Overview
• 9.2. China Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Tumor Infiltrating Lymphocytes Market

• 10.1. India Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Tumor Infiltrating Lymphocytes Market

• 11.1. Japan Tumor Infiltrating Lymphocytes Market Overview
• 11.2. Japan Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Tumor Infiltrating Lymphocytes Market

• 12.1. Australia Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Tumor Infiltrating Lymphocytes Market

• 13.1. Indonesia Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Tumor Infiltrating Lymphocytes Market

• 14.1. South Korea Tumor Infiltrating Lymphocytes Market Overview
• 14.2. South Korea Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Tumor Infiltrating Lymphocytes Market

• 15.1. Western Europe Tumor Infiltrating Lymphocytes Market Overview
• 15.2. Western Europe Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Tumor Infiltrating Lymphocytes Market

• 16.1. UK Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Tumor Infiltrating Lymphocytes Market

• 17.1. Germany Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Tumor Infiltrating Lymphocytes Market

• 18.1. France Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Tumor Infiltrating Lymphocytes Market

• 19.1. Italy Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Tumor Infiltrating Lymphocytes Market

• 20.1. Spain Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Tumor Infiltrating Lymphocytes Market

• 21.1. Eastern Europe Tumor Infiltrating Lymphocytes Market Overview
• 21.2. Eastern Europe Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Tumor Infiltrating Lymphocytes Market

• 22.1. Russia Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Tumor Infiltrating Lymphocytes Market

• 23.1. North America Tumor Infiltrating Lymphocytes Market Overview
• 23.2. North America Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Tumor Infiltrating Lymphocytes Market

• 24.1. USA Tumor Infiltrating Lymphocytes Market Overview
• 24.2. USA Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Tumor Infiltrating Lymphocytes Market

• 25.1. Canada Tumor Infiltrating Lymphocytes Market Overview
• 25.2. Canada Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Tumor Infiltrating Lymphocytes Market

• 26.1. South America Tumor Infiltrating Lymphocytes Market Overview
• 26.2. South America Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Tumor Infiltrating Lymphocytes Market

• 27.1. Brazil Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Tumor Infiltrating Lymphocytes Market

• 28.1. Middle East Tumor Infiltrating Lymphocytes Market Overview
• 28.2. Middle East Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Tumor Infiltrating Lymphocytes Market

• 29.1. Africa Tumor Infiltrating Lymphocytes Market Overview
• 29.2. Africa Tumor Infiltrating Lymphocytes Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Tumor Infiltrating Lymphocytes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Tumor Infiltrating Lymphocytes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Tumor Infiltrating Lymphocytes Market Competitive Landscape And Company Profiles

• 30.1. Tumor Infiltrating Lymphocytes Market Competitive Landscape
• 30.2. Tumor Infiltrating Lymphocytes Market Company Profiles
  • 30.2.1. Bellicum Pharmaceuticals Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Novartis AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Pfizer Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Precision BioScience Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bluebird Bio Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Tumor Infiltrating Lymphocytes Market Competitive Benchmarking

32. Global Tumor Infiltrating Lymphocytes Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Tumor Infiltrating Lymphocytes Market

34. Tumor Infiltrating Lymphocytes Market Future Outlook and Potential Analysis

• 34.1 Tumor Infiltrating Lymphocytes Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Tumor Infiltrating Lymphocytes Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Tumor Infiltrating Lymphocytes Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer